CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 511 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01464333
NCT01464333N/ACompleted

Humira® for Subcutaneous Injection Protocol for Special Investigation (Long-term Treatment for Crohn's Disease Patients)

AbbVie (prior sponsor, Abbott)·observational·Posted Nov 3, 2011·Updated May 20, 2019

In Brief

An observational study for Crohn's Disease. Completed, enrolled 511 participants.

Detailed Summary

This study of Humira will be conducted to obtain information on the safety (especially profile of malignant tumors and serious infections) and effectiveness in patients with Crohn's disease who are receiving Humira for a long period of time.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 3, 2011
Enrollment StartDec 16, 2011
Primary CompletionMar 31, 2018
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 14.7 years ago